Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations
The DOI matches its Crossref record; 344 of the 344 references it cites were found in a registry or an index.
Abstract
With the widespread use of atypical or second-generation antipsychotics, switching treatment has become current practice and more complicated, as the pharmacological profiles of these agents differ substantially despite their similarity in being 'atypical'. All share the ability to block dopamine D₂ receptors, and most of them also block serotonin 5-HT2A receptors. Apart from these common features, some atypical antipsychotics are also able to block or stimulate other dopamine or serotonin receptors, as well as histaminergic, muscarinergic or adrenergic receptors. As a result of the varying receptor affinities, in switching or discontinuing compounds several possible pitfalls have to be considered, including the occurrence of withdrawal and rebound syndromes. This article reviews the pharmacological background of functional blockade or stimulation of receptors of interest in regard to atypical antipsychotics and the implicated potential withdrawal and rebound phenomena. A MEDLINE search was carried out to identify information on withdrawal or rebound syndromes occurring after discontinuation of atypical antipsychotics. Using the resulting literature, we first discuss the theoretical background to the functional consequences of atypical antipsychotic-induced blockade or stimulation of neurotransmitter receptors and, secondly, we highlight the clinical consequences of this. We then review the available clinical literature on switching between atypical antipsychotics, with respect to the occurrence of withdrawal or rebound symptoms. Finally, we offer practical recommendations based on the reviewed findings. The systematic evaluation of withdrawal or rebound phenomena using randomized controlled trials is still understudied. Knowledge of pharmacological receptor-binding profiles may help clinicians in choosing adequate switching or discontinuation strategies for each agent. Results from large switching trials indicate that switching atypical antipsychotics can be performed in a safe manner. Treatment-emergent adverse events during or after switching are not always considered to be, at least in part, associated with the pre-switch antipsychotic. Further studies are needed to substantiate the evidence gained so far on different switching strategies. The use of concomitant medication, e.g., benzodiazepines or anticholinergic drugs, may help to minimize symptoms arising from the discontinuation or switching of antipsychotic treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [20]
In the citing paper
“Third, although the principal therapeutic effects of antipsychotics are attributed to D2 antagonism, other receptor targets, including 5HT2 and 5HT1A, have also been thought relevant, and these receptors, and others, such as cholinergic receptors, may also determine withdrawal effects.20”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [20]
In the citing paper
“Studies on withdrawal reactions associated with antipsychotics switch were extensively reviewed also by Cerovecki et al. [8] and similar conclusions were reached.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
In the citing paper
“New withdrawal symptoms following dose decrease, discontinuation, or switch may occur with any type of antipsychotic and include a wide range of symptoms [8, 9] which are reported in Table 4.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
In the citing paper
“Overall, SGAs are associated as frequently with new withdrawal symptoms as FGAs, when we take into consideration the early 1960-1970 studies of FGAs.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [8]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Ungerstedt, U. (1971) · Acta Physiologica Scandinavica · doi:10.1111/j.1365-201x.1971.tb11000.x · Cited by 1,922
Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
Arrang, J.-M., Garbarg, M., & Schwartz, J.-C. (1983) · Nature · doi:10.1038/302832a0 · Cited by 1,575
Fuxe, K. (1965) · Zeitschrift f�r Zellforschung und Mikroskopische Anatomie · doi:10.1007/bf00337069 · Cited by 1,564
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Dahlstroem, A., & Fuxé, K. (1965) · PubMed · Cited by 1,015
The physiology of brain histamine
Brown, R. E., Stevens, D. R., & Haas, H. L. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00039-3 · Cited by 988
Histaminergic transmission in the mammalian brain
Schwartz, J. C., Arrang, J. M., Garbarg, M., Pollard, H., & Ruat, M. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.1.1 · Cited by 944
The role of histamine and the tuberomamillary nucleus in the nervous system
Haas, H., & Panula, P. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1034 · Cited by 929
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
International Union of Pharmacology. XIII. Classification of Histamine Receptors
Hill, S. J., Ganellin, C. R., Timmerman, H., Schwartz, J. C., Shankley, N. P., Young, J. M., Schunack, W., Levi, R., & Haas, H. L. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01328-0 · Cited by 899
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Structure and function of dopamine receptors
Vallone, D., Picetti, R., & Borrelli, E. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00063-9 · Cited by 818
Demonstration and mapping out of nigro-neostriatal dopamine neurons
Andén, N.-E., Carlsson, A., Dahlström, A., Fuxe, K., Hillarp, N.-Å., & Larsson, K. (1964) · Life Sciences · doi:10.1016/0024-3205(64)90161-4 · Cited by 813
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Zahrt, J., Taylor, J. R., Mathew, R. G., & Arnsten, A. F. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08528.1997 · Cited by 796
Psychopharmacology: The Fourth Generation of Progress
Kramlinger, K. G. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.10.1021-a · Cited by 779
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Clinical Uses of α2-Adrenergic Agonists
Kamibayashi, T., Maze, M., Weiskopf, R. B., Weiskopf, R. B., & Todd, M. M. (2000) · Anesthesiology · doi:10.1097/00000542-200011000-00030 · Cited by 714
Binding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607
Arnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549
Granon, S., Passetti, F., Thomas, K. L., Dalley, J. W., Everitt, B. J., & Robbins, T. W. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-03-01208.2000 · Cited by 546
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493
Cardiovascular Regulation in Mice Lacking α 2 -Adrenergic Receptor Subtypes b and c
Link, R. E., Desai, K., Hein, L., Stevens, M. E., Chruscinski, A., Bernstein, D., Barsh, G. S., & Kobilka, B. K. (1996) · Science · doi:10.1126/science.273.5276.803 · Cited by 467
Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia
Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & H??schl, C. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00004 · Cited by 461
Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167346 · Cited by 438
Levey, A., Edmunds, S., Koliatsos, V, Wiley, R., & Heilman, C. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04077.1995 · Cited by 422
Muscarinic acetylcholine receptors as CNS drug targets
Langmead, C. J., Watson, J., & Reavill, C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.009 · Cited by 419
The Expert Consensus Guideline Series
Karceski, S., Morrell, M., & Carpenter, D. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2001.0283 · Cited by 396
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Lakhlani, P. P., MacMillan, L. B., Guo, T. Z., McCool, B. A., Lovinger, D. M., Maze, M., & Limbird, L. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9950 · Cited by 360
Dopamine supersensitivity correlates with D2Highstates, implying many paths to psychosis
Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., Premont, R. T., Sotnikova, T. D., Boksa, P., El-Ghundi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409766102 · Cited by 352
Molecular Cloning and Characterization of a New Human Histamine Receptor, HH4R
Nakamura, T., Itadani, H., Hidaka, Y., Ohta, M., & Tanaka, K. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4008 · Cited by 351
Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors
Schlicker, E., Fink, K., Detzner, M., & G�thert, M. (1993) · Journal of Neural Transmission · doi:10.1007/bf01244933 · Cited by 339
BindingDB (2011) · PubMed · doi:10.7270/q2cr5rw8 · Cited by 333
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 323
Seeger, T. F., Seymour, P. A., Schmidt, A. W., Zorn, S. H., Schulz, D. W., Lebel, L. A., McLean, S., Guanowsky, V, Howard, H. R., & Lowe, J. A. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12023-5 · Cited by 322
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Subtypes of functional α1- and α2-adrenoceptors
Docherty, J. R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00682-7 · Cited by 311
Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex
Schlicker, E., Betz, R., & G�thert, M. (1988) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00182737 · Cited by 311
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301
Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus
Volpicelli, L. A., & Levey, A. I. (2004) · Progress in Brain Research · doi:10.1016/s0079-6123(03)45003-6 · Cited by 298
Dopamine receptor subtypes: beyond the D1/D2 classification
Andersen, P. H., Gingrich, J. A., Bates, M. D., Dearry, A., Falardeau, P., Senogles, S. E., & Caron, M. G. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90249-8 · Cited by 293
Towards a muscarinic hypothesis of schizophrenia
Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 291
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
Birnbaum, S., Gobeske, K. T., Auerbach, J., Taylor, J. R., & Arnsten, A. F. T. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00138-9 · Cited by 281
Correll, C. U. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)71701-6 · Cited by 273
Dopaminergic supersensitivity after neuroleptics: time-course and specificity
Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271 · cited 1×
“Such an increase in hypersensitivity has been thought to be responsible for the occurrence of TD after longer treatment durations with D2 receptor antagonists, especially with high-potency conventional antipsychotics [42].”
BackgroundVilaró, M. T., Palacios, J., & Mengod, G. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90064-g · Cited by 268
Citrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02228.x · Cited by 266
Hough, D., Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., & Eerdekens, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.10.026 · Cited by 265
Mrzljak, L., Levey, A. I., & Goldman-Rakic, P. S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5194 · Cited by 256
Ferry, B., Roozendaal, B., & McGaugh, J. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00157-2 · Cited by 251
Kane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169cca7 · Cited by 250
Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors
Schlicker, E., Fink, K., Hinterthaner, M., & G�thert, M. (1989) · Naunyn-Schmiedebergs Archives of Pharmacology · doi:10.1007/bf00717738 · Cited by 250
Meltzer, H. Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu, J., Kalali, A. H., Schweizer, E., Pikalov, A., & Loebel, A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10060907 · Cited by 250
In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems
MELTZER, H., & HUANG, M. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00909-6 · Cited by 248
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 1×
“From a clinical point of view the worsening of negative symptoms and the evocation of rebound phenomena might be explained by the increase in symptoms of fear [67].”
Backgroundα-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function
Arnsten, A. F. T., Mathew, R., Ubriani, R., Taylor, J. R., & Li, B.-M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00296-0 · Cited by 245
Ferry, B., Roozendaal, B., & McGaugh, J. L. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05119.1999 · Cited by 243
The 5-HT7 receptor and disorders of the nervous system: an overview
Hedlund, P. B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1626-0 · Cited by 239
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Kane, J. M., Leucht, S., Carpenter, D. P., & Docherty, J. P. (2003) · PubMed · Cited by 234
Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease
Flynn, D. D., Ferrari‐DiLeo, G., Mash, D. C., & Levey, A. I. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64041888.x · Cited by 234
Does switching to a new antipsychotic improve outcomes?
Rosenheck, R. A., Davis, S., Covell, N., Essock, S., Swartz, M., Stroup, S., McEvoy, J., & Lieberman, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.031 · Cited by 232
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231 · cited 7×
“Supersensitivity syndromes subsume tardive dyskinesias (TD) and supersensitivity psychosis, sometimes also called ‘‘rapid-onset psychosis’’ [12].”
BackgroundInfluentialThe Serotonin1A A Receptor: A Representative Member of the Serotonin Receptor Family
Pucadyil, T. J., Kalipatnapu, S., & Chattopadhyay, A. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-005-3969-3 · Cited by 229
Adrenoceptors and signal transduction in neurons
Hein, L. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0285-2 · Cited by 226
Neuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Getting specialized: presynaptic and postsynaptic dopamine D2 receptors
De Mei, C., Ramos, M., Iitaka, C., & Borrelli, E. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.002 · Cited by 221
The role of 5-HT2A receptors in antipsychotic activity
Schmidt, C. J., Sorensen, S. M., Kenne, J. H., Carr, A. A., & Palfreyman, M. G. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00210-w · Cited by 215
Freedman, R., Adams, C. E., & Leonard, S. (2000) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(00)00109-5 · Cited by 214
Multiple Serotonin Receptors: Clinical and Experimental Aspects
Roth, B. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148985 · Cited by 213
Urichuk, L., Prior, T., Dursun, S., & Baker, G. (2008) · Current Drug Metabolism · doi:10.2174/138920008784746373 · Cited by 204
Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Tarsy, D., & Baldessarini, R. J. (2006) · Movement Disorders · doi:10.1002/mds.20823 · Cited by 200
Activation of the noradrenergic system facilitates an attentional shift in the rat
Devauges, V., & Sara, S. J. (1990) · Behavioural Brain Research · doi:10.1016/0166-4328(90)90118-x · Cited by 200
Sallinen, J., Haapalinna, A., Viitamaa, T., Kobilka, B. K., & Scheinin, M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-03035.1998 · Cited by 196
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111609 · Cited by 193
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., & Loebel, A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191
The dopamine D4 receptor: biochemical and signalling properties
Rondou, P., Haegeman, G., & Craenenbroeck, K. V. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0293-y · Cited by 177
Kramer, M., Litman, R., Hough, D., Lane, R., Lim, P., Liu, Y., & Eerdekens, M. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990988 · Cited by 176
Potkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175
Inverse Agonist Activity of Atypical Antipsychotic Drugs at Human 5-Hydroxytryptamine2C Receptors
Herrick-Davis, K., Grinde, E., & Teitler, M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38891-3 · Cited by 173
Effectiveness of Switching Antipsychotic Medications
Essock, S. M., Covell, N. H., Davis, S. M., Stroup, T. S., Rosenheck, R. A., & Lieberman, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2090 · Cited by 172
Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?
Meltzer, H. Y., & Sumiyoshi, T. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.016 · Cited by 172
Sallinen, J., Link, R. E., Haapalinna, A., Viitamaa, T., Kulatunga, M., Sjöholm, B., Macdonald, E., Pelto-Huikko, M., Leino, T., Barsh, G. S., et al. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.1.36 · Cited by 172
Nasrallah, H. A., Gopal, S., Gassmann-Mayer, C., Quiroz, J. A., Lim, P., Eerdekens, M., Yuen, E., & Hough, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.79 · Cited by 170
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · cited 2×
“It has been proposed that symptoms associated with the discontinuation of psychotropic drugs be separated into three different types [1]: (1) withdrawal symptoms (minor and major new symptoms [2]) (2) rebound syndromes and (3) supersensitivity syndromes [1, 3–5].”
BackgroundSerotonergic regulation of neuronal excitability in the prefrontal cortex
Andrade, R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.015 · Cited by 167
Joseph, J. D., Wang, Y.-M., Miles, P. R., Budygin, E. A., Picetti, R., Gainetdinov, R. R., Caron, M. G., & Wightman, R. M. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00067-2 · Cited by 162
Dopamine Receptor Gene Expression in the Human Medial Temporal Lobe
Meador-Woodruff, J. H., Grandy, D. K., Van Tol, H. H. M., Damask, S. P., Little, K. Y., Civelli, O., & Watson, S. J. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.27 · Cited by 159
Moser, M., Trommald, M., Egeland, T., & Andersen, P. (1997) · Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19970414)380:3<373::aid-cne6>3.0.co;2-# · Cited by 157
α-Adrenoceptor modulation hypothesis of antipsychotic atypicality
Svensson, T. H. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.009 · Cited by 156
Yanai, K., Son, L. Z., Endou, M., Sakurai, E., Nakagawasai, O., Tadano, T., Kisara, K., Inoue, I., Watanabe, T., & Watanabe, T. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00167-5 · Cited by 155
Noradrenaline contractions of human prostate mediated by α1c‐(α1c‐) adrenoceptor subtype
Marshall, I., Burt, R. P., & Chappie, C. R. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15001.x · Cited by 155
Serotonergic involvement in haloperidol-induced catalepsy.
Neal‐Beliveau, B. S., Joyce, J. N., & Lucki, I. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38100-0 · Cited by 148
Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertuğrul, A., & Meltzer, H. Y. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.06.008 · Cited by 147
Muscarinic mechanisms of antipsychotic atypicality
Bymaster, F. P., Felder, C. C., Tzavara, E. T., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.008 · Cited by 146
Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin1A receptors
Kusserow, H., Davies, B., Hörtnagl, H., Voigt, I., Stroh, T., Bert, B., Deng, D. R., Fink, H., Veh, R. W., & Theuring, F. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.06.028 · Cited by 145
Involvement of α1-adrenoceptors in the basolateral amygdala in modulation of memory storage
Ferry, B., Roozendaal, B., & McGaugh, J. L. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00169-7 · Cited by 143
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
Glazer, W. M. (2000) · PubMed · Cited by 143
Adrenergic targets for the treatment of cognitive deficits in schizophrenia
Arnsten, A. F. T. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1724-3 · Cited by 141
Lurasidone: a new drug in development for schizophrenia
Meyer, J. M., Loebel, A. D., & Schweizer, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286388 · Cited by 141
Masaki, T., Yoshimatsu, H., Chiba, S., Watanabe, T., & Sakata, T. (2001) · Diabetes · doi:10.2337/diabetes.50.2.385 · Cited by 139
Shen, K., & Johnson, S. W. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00331.x · Cited by 137
Garcia, M., Florán, B., Arias‐Montaño, J., Young, J. M., & Aceves, J. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00100-0 · Cited by 135
Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain
Vizuete, M., Traiffort, É., Bouthenet, M.-L., Ruat, M., Souil, E., Tardivel‐Lacombe, J., & Schwartz, J. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00010-9 · Cited by 134
Codony, X., Vela, J. M., & Ramírez, M. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.01.004 · Cited by 134
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
Meltzer, H. Y., Horiguchi, M., & Massey, B. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2137-8 · Cited by 134
Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine?
Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E., & Cohen, B. M. (1992) · British Journal of Psychiatry · doi:10.1192/s0007125000296852 · Cited by 134
Citrome, L. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02587.x · Cited by 130
Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130
Presynaptic control of serotonin on striatal dopamine function
Navailles, S., & Deurwaerdère, P. D. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2029-y · Cited by 127
Neuronal histamine in the hypothalamus suppresses food intake in rats
Ookuma, K., Sakata, T., Fukagawa, K., Yoshimatsu, H., Kurokawa, M., Machidori, H., & Fujimoto, K. (1993) · Brain Research · doi:10.1016/0006-8993(93)90960-u · Cited by 126
Kane, J. M., Cohen, M., Zhao, J., Alphs, L., & Panagides, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d35d6b · Cited by 126
Novelty seeking behavior in the rat is dependent upon the integrity of the noradrenergic system
Sara, S. J., Dyon-Laurent, C., & Hervé, A. (1995) · Cognitive Brain Research · doi:10.1016/0926-6410(95)90007-1 · Cited by 125
(2008) · PubMed · Cited by 124
Severe cases of neuroleptic-induced supersensitivity psychosis
Chouinard, G. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90050-2 · Cited by 123
Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone
Weiden, P. J., Daniel, D. G., Simpson, G., & Romano, S. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095347.32154.08 · Cited by 123
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
Keck Jr, P. E., & McElroy, S. L. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.655 · Cited by 120
Severe and Uncommon Involuntary Movement Disorders due to Psychotropic Drugs
(2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815511 · Cited by 118
Role of histamine in rodent antinociception
Malmberg‐Aiello, P., Lamberti, C., Ghelardini, C., Giotti, A., & Bartolini, A. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb14883.x · Cited by 118
Knaus, A., Muthig, V., Schickinger, S., Moura, E., Beetz, N., Gilsbach, R., & Hein, L. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.036 · Cited by 117
Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus
Fukagawa, K., Sakata, T., Shiraishi, T., Yoshimatsu, H., Fujimoto, K., Ookuma, K., & Wada, H. (1989) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1989.256.3.r605 · Cited by 115
Upcoming Agents for the Treatment of Schizophrenia: Mechanism of Action, Efficacy and Tolerability
Bishara, D., & Taylor, D. M. (2008) · Drugs · doi:10.2165/0003495-200868160-00002 · Cited by 113
Cutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169d4ce · Cited by 113
Alcantara, A. A., Mrzljak, L., Jakab, R. L., Levey, A. I., Hersch, S. M., & Goldman‐Rakic, P. S. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1186 · Cited by 112
Therapeutic Role of 5-HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease
Ohno, Y. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00211.x · Cited by 108
Dopamine and norepinephrine activity in schizophrenia
van Kammen, D. P., & Kelley, M. E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90032-m · Cited by 105
Harvey, P. D., Meltzer, H. Y., Simpson, G. M., Potkin, S. G., Loebel, A. D., SIU, C. O., & Romano, S. J. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.07.009 · Cited by 104
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
Scarr, E., & Dean, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05711.x · Cited by 104
Kim, K.-S., Pae, C.-U., Chae, J.-H., Bahk, W.-M., Jun, T.-Y., Kim, D.-J., & Dickson, R. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0506 · Cited by 104
Gopal, S., Vijapurkar, U., Lim, P., Morozova, M., Eerdekens, M., & Hough, D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110372817 · Cited by 103
Clozapine Withdrawal_Emergent Dystonias and Dyskinesias: A Case Series
Ahmed, S., Chengappa, K. N. R., Naidu, V. R., Baker, R. W., Parepally, H., & Schooler, N. R. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0906 · Cited by 103
Efficacy of Iloperidone in the Treatment of Schizophrenia: Initial Phase 3 Studies
Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181692787 · Cited by 102
Cerebellar norepinephrine depletion and impaired acquisition of specific locomotor tasks in rats
Watson, M., & McElligott, J. G. (1984) · Brain Research · doi:10.1016/0006-8993(84)90518-3 · Cited by 102
Kalkman, H. O., Subramanian, N., & Hoyer, D. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00285-8 · Cited by 99
α2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
Kalkman, H. O., & Loetscher, E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01308-6 · Cited by 96
Psychopharmacology of Central Serotonergic Systems
Baumgarten, H., & Grozdanovic, Z. (1995) · Pharmacopsychiatry · doi:10.1055/s-2007-979623 · Cited by 94
Safety Profile of Iloperidone: A Pooled Analysis of 6-Week Acute-Phase Pivotal Trials
Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181694f5a · Cited by 94
Scheibner, J., Trendelenburg, A., Hein, L., & Starke, K. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703882 · Cited by 92
Bonsi, P., Martella, G., Cuomo, D., Platania, P., Sciamanna, G., Bernardi, G., Wess, J., & Pisani, A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1678-08.2008 · Cited by 91
Synthesis, trafficking, and localization of muscarinic acetylcholine receptors
Nathanson, N. M. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.006 · Cited by 90
Iloperidone binding to human and rat dopamine and 5-HT receptors
Kongsamut, S., Roehr, J. E., Cai, J., Hartman, H. B., Weissensee, P., Kerman, L. L., Tang, L., & Sandrasagra, A. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00840-0 · Cited by 90
Traiffort, É., Pollard, H., Moreau, J., Ruat, M., Schwartz, J., Martinez-Mir, M. I., & Palacios, J. M. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08903.x · Cited by 89
Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal
Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Remington, G. J., & Kapur, S. (1999) · PubMed · Cited by 88
Ritchie, C. W., Chiu, E., Harrigan, S., Hall, K., Hassett, A., Macfarlane, S., Mastwyk, M., O'Connor, D. W., Opie, J., & Ames, D. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.862 · Cited by 88
Byerly, M., Marcus, R. N., Tran, Q.-V., Eudicone, J. M., Whitehead, R. E., & Baker, R. A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.019 · Cited by 88
Switching Antipsychotic Medications: General Recommendations and Switching to Amisulpride
Burns, T., Chabannes, J.-P., & Demyttenaere, K. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000589 · Cited by 88
Hsieh, G. C., Chandran, P., Salyers, A. K., Pai, M., Zhu, C., Wensink, E. J., Witte, D. G., Miller, T. R., Mikusa, J. P., Baker, S. J., et al. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.12.004 · Cited by 87
Change in sexual dysfunction with aripiprazole: a switching or add-on study
Mir, A., Shivakumar, K., Williamson, R. J., McAllister, V., O'Keane, V., & Aitchison, K. J. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082901 · Cited by 86
Prinssen, E. P. M., Colpaert, F. C., & Koek, W. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02430-5 · Cited by 86
Characterization of histamine H3receptors regulating acetylcholine release in rat entorhinal cortex
Arrang, J., Drutel, G., & Schwartz, J. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13379.x · Cited by 86
Rouse, S. T., Edmunds, S. M., Yi, H. L., Gilmor, M. L., & Levey, A. I. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01011-9 · Cited by 85
Interactions between antiepileptics and second-generation antipsychotics
de León, J., Santoro, V., D’Arrigo, C., & Spina, E. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.660918 · Cited by 85
Mercer, L. P., Kelley, D. S., Humphries, L. L., & Dunn, J. D. (1994) · Journal of Nutrition · doi:10.1093/jn/124.7.1029 · Cited by 84
Dopamine D2 and D4 receptor ligands: relation to antipsychotic action
Wilson, J. M., Sanyal, S., & Tol, H. H. M. V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00312-4 · Cited by 84
Schoemaker, J., Naber, D., Vrijland, P., Panagides, J., & Emsley, R. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1248313 · Cited by 84
Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons
Kjær, A., Knigge, U., Rouleau, A., Garbarg, M., & Warberg, J. (1994) · Endocrinology · doi:10.1210/endo.135.2.8033816 · Cited by 84
Marcus, M. M., Jardemark, K. E., Wadenberg, M.-L., Langlois, X., Hertel, P., & Svensson, T. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005328 · Cited by 83
Histamine receptors: subclasses and specific ligands
Haaksma, E. E. J., Leurs, R., & Timmerman, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90046-5 · Cited by 82
Privou, C., Knoche, A., Hasenöhrl, R. U., & Huston, J. P. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00087-2 · Cited by 81
Kane, J. M., Mackle, M., Snow-Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06306 · Cited by 80
Haddad, P. M., Das, A., Keyhani, S., & Chaudhry, I. B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111424929 · Cited by 78
The dopamine D4 receptors and mechanisms of antipsychotic atypicality
Wong, A. H. C., & Tol, H. H. M. V. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.005 · Cited by 77
Akhondzadeh, S., Malek-Hosseini, M., Ghoreishi, A., Raznahan, M., & Rezazadeh, S. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.08.020 · Cited by 77
M1 Agonists for the Treatment of Alzheimer's Disease.: Novel Properties and Clinical Updatea
FISHER, A., HELDMAN, E., GURWITZ, D., HARING, R., KARTON, Y., MESHULAM, H., PITTEL, Z., MARCIANO, D., BRANDEIS, R., SADOT, E., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34418.x · Cited by 76
Xu, T.-X., Sotnikova, T. D., Liang, C., Zhang, J., Jung, J. U., Spealman, R. D., Gainetdinov, R. R., & Yao, W.-D. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0974-09.2009 · Cited by 76
Properties and Roles of the Three Subclasses of Histamine Receptors in Brain
Schwartz, J.-C., Arrang, J., Garbarg, M., & Körner, M. (1986) · Journal of Experimental Biology · doi:10.1242/jeb.124.1.203 · Cited by 76
Watanabe, T., & Yanai, K. (2001) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.195.197 · Cited by 75
Gopal, S., Gassmann-Mayer, C., Palumbo, J., Samtani, M. N., Shiwach, R., & Alphs, L. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903482772 · Cited by 73
Brown, R. E., & Reymann, K. G. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021675 · Cited by 73
Samtani, M. N., Gopal, S., Gassmann-Mayer, C., Alphs, L. D., & Palumbo, J. (2011) · CNS Drugs · doi:10.2165/11591690-000000000-00000 · Cited by 72
??2-Adrenoceptor Antagonists: A New Approach to Parkinson??s Disease?
Brefel‐Courbon, C., Thalamas, C., Paul, H. P. S., Sénard, J., Montastruc, J., & Rascol, O. (1998) · CNS Drugs · doi:10.2165/00023210-199810030-00004 · Cited by 71
Olianas, M. C., Maullu, C., & Onali, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00048-7 · Cited by 71
Spreng, M., Cotecchia, S., & Schenk, F. (2001) · Neurobiology of Learning and Memory · doi:10.1006/nlme.2000.3965 · Cited by 71
Mrzljak, L., Levey, A. I., Belcher, S., & Goldman-Rakic, P. S. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980105)390:1<112::aid-cne10>3.0.co;2-z · Cited by 71
Strategies for Switching From Conventional Antipsychotic Drugs or Risperidone to Olanzapine
Kinon, B. J., Basson, B. R., Gilmore, J. A., Malcolm, S., & Stauffer, V. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1105 · Cited by 70
Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study
Lee, B.-H., Kim, Y., & Park, S.-H. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.02.001 · Cited by 70
Mechanism of histamine‐induced antidiuretic response
Kp, B., Kulshrestha, V. K., Santhakumari, G., & SRIVASTAVA, Y. P. (1973) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1973.tb08196.x · Cited by 68
Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. L., Naber, D., Priori, S., Sturkenboom, M., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01563.x · Cited by 67 · cited 1×
“Sertindole is considered a second-line treatment option in schizophrenic patients given its overall higher cardiac mortality [168].”
BackgroundRelapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine
Meltzer, H. Y., Lee, M. A., Ranjan, R., Mason, E. A., & Cola, P. A. (1996) · Psychopharmacology · doi:10.1007/bf02245619 · Cited by 67
Turrone, P., Remington, G. J., Kapur, S., & Nóbrega, J. N. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300233 · Cited by 67
α2-Adrenergic control of dopamine overflow and metabolism in mouse striatum
Yavich, L., Lappalainen, R. I., Sirviö, J., Haapalinna, A., & MacDonald, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01375-7 · Cited by 65
Tokita, S., Takahashi, K., & Kotani, H. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj06001x4 · Cited by 64
Kosinski, C. M., Standaert, D. G., Counihan, T. J., Scherzer, C. R., Kerner, J. A., Daggett, L. P., Veli�elebi, G., Penney, J. B., Young, A. B., & Landwehrmeyer, G. B. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980105)390:1<63::aid-cne6>3.0.co;2-o · Cited by 63
Balle, T., Perregaard, J., Ramirez, M. T., Larsen, A. K., Søby, K. K., Liljefors, T., & Andersen, K. V. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020938y · Cited by 63
Hagan, R. M., Kilpatrick, G. J., & Tyers, M. B. (1993) · Psychopharmacology · doi:10.1007/bf02245009 · Cited by 63
Franowicz, J. S., & Arnsten, A. F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00060-3 · Cited by 62
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
Marcus, M. M., Wiker, C., Frånberg, O., Konradsson‐Geuken, Å., Langlois, X., Jardemark, K. E., & Svensson, T. H. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990794 · Cited by 60
Research works printed but not linked: 2
- Lu ML, Pan JJ, Teng HW, et al. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother. 2002;36(9):1387–90. · doi:10.1345/aph.1a440 · Paper page
- Cucchiaro J, Potkin SG, Ogasa M, et al. A double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Bull. 2009;35(Suppl. 1):342–3.
Cited by
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
“In this scenario, unless cross-titration is used, and depending on the relative half-lives of the discontinued and the new drug, the patient can suffer from temporary underdosing or overdosing.(35,235)”
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1713091 · Cited by 216
Self-citation
Metadata
- Authors
- Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Vitos (DE)
- University of Regensburg (DE)
- University of Bonn (DE)
- Bệnh viện Đa khoa Xanh Pôn (VN)
- Corresponding author
- Musil, Richard
- Venue
- CNS Drugs
- Published
- 2013-07
- Volume
- 27
- Issue
- 7
- Pages
- 545-572
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2016329927
- Cited by
- 112
- References
- 341
- Citations by year
- 2026: 15 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 11 · 2016: 7 · 2015: 4 · 2014: 4 · 2013: 1
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- atypical antipsychotics, antipsychotic switching, antipsychotic discontinuation, withdrawal symptoms, dopamine D2 receptor blockade, receptor binding profiles, treatment-emergent adverse events, benzodiazepines, anticholinergic agents, schizophrenia
- MeSH terms
- Animals, Drug Administration Schedule, Humans, Psychoses, Substance-Induced, Substance Withdrawal Syndrome, Antipsychotic Agents, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.